FLU FACTS FOR PANDEMIC PLANNERS - PowerPoint PPT Presentation

1 / 18
About This Presentation
Title:

FLU FACTS FOR PANDEMIC PLANNERS

Description:

H - hemagglutinin (HA): receptor binding surface glycoprotein (400 spikes) ... Concerns: Bronchospasm in COPD/Asthma Young children use of inhaler ... – PowerPoint PPT presentation

Number of Views:30
Avg rating:3.0/5.0
Slides: 19
Provided by: Staf702
Category:

less

Transcript and Presenter's Notes

Title: FLU FACTS FOR PANDEMIC PLANNERS


1
FLU FACTS FOR PANDEMIC PLANNERS
  • John D. Malone, MD, MPH
  • Infectious Diseases
  • Center for Biological Monitoring and Modeling
  • Pacific Northwest National Laboratory
  • Richland, Washington
  • John.Malone_at_pnl.gov 509-376-9635 619-838-7784

2
INFLUENZA VIRUS STRUCTURE
  • H - hemagglutinin (HA) receptor binding surface
    glycoprotein (400 spikes) results in viral
    entry by fusion with respiratory cells (sialic
    acid)
  • N neuraminidase (NA) glycoprotein (100 spikes)
    mediates newly formed flu virus release from
    respiratory cells (breaks sialic acid bonds)
  • RNA single strand high error replication
    rate Reassortment (mixing) 8 viral genes when
    cell infected with 2 different viral strains
  • Genus Influenza 3 types A, B, C A occurs
    vertebrates (birds/swine) B, C primarily
    human Ref Transmission of Epidemic
    Influenza, Plenum Press,1992

3
INFLUENZA
4
(No Transcript)
5
PANDEMIC INFLUENZA THREAT
  • Major Pandemics 1918 Spanish Influenza -
    H1N1 (W epi curve) 1957 Asian Influenza -
    H2N2 1968 Hong Kong H3N2 (A/Hong
    Kong/1/68)
  • Flu virus adaption bird ? human ? human through
    reassortment (1957/1968 pandemic) antigenic
    drift minor change (point mutations) H/N
    antigenic shift major genetic reassortment H
    gene
  • Only 1 amino acid (serine) change in PB1 gene in
    respect to avian strains shared among all 3
    pandemics Nature 2005437889
  • 1997 Avian H5N1 SE Asia
    poultry/migratory birds/pigs (human/animal) gt200
    human cases, gt 50 mortality J Infect Dis
    2006194S77-81//PNAS 2006103 (Nov 7)16936

6
H5N1 EPIDEMIOLOGY 27 DEC 2006
  • 261 Human cases in 10 countries Dead - 157
    (60)
  • Top Four Countries cases and mortality rate
    () Viet Nam - 93 (45) Indonesia - 74
    (77) China - 21 (67) Egypt -
    18 (56)
  • Majority close contact poultry/1case human/human
  • Constantly changing 2 clades (genetic distinct
    groups) 3 distinct sub clades
  • Air flights Seattle major hub United (Fly
    the Friendly Sky's) starting direct to China
    SARS traced to Metropole Hotel Hong Kong
    Chinese doctor infected others (elevator?)
  • Airplane transmission example Iowa Mumps
    outbreak 2 cases transmitted in flight 11
    possible infected 575 exposed 33 commercial
    flights 8 airlines MMWR 200655559

7
(No Transcript)
8
PEDIATRIC POPULATION
  • Young children (daycare/initial elementary
    age) High influenza attack rate - 40 Secrete
    virus prolonged period - (5-7 days) Asymptomatic
    period before clinical illness
  • The pediatric population experiences preventable
    hospitalizations and serves as a reservoir for
    influenza and its transmission to other children
    as well as adultsoseltamivir therapy accelerated
    resolution of clinical illnessresistance was not
    a frequent event, but has been documented in
    Japanese children treated with this
    medication Whitley RJ, Monto AS. J Infect Dis
    2006 (Nov 1) Suppl 2S133-8

9
INFLUENZA PEDIATRIC POPULATION
  • Clinical presentation varies by age group Older
    children/adults fever, cough, headache,
    myalgia, sore throat, runny nose Younger
    children (lt5 yo) fever, cough, runny nose
    (similar to all common pathogens rsv,
    paraflu, common cold) Infants fever alone
  • Attack rates pre-school and school age - 15-42
  • Otitis media/bacterial pneumonia flu associated
  • High risk hospitalization ? lt 5 yo, ? ? lt
    1yo ACIP 2004 universal flu shot Kids 6-59
    m Pregnancy any trimester (cover lt 6 m)
    MMWR 200655(RR10)1

10
SCHOOL AGE CHILDREN FLU TRANSMISSION
  • Tecumsah, MI 1968 study Elementary/High school
    vaccinated against Hong Kong (AH3N2) pandemic.
    Significantly lower rate resp Ilness age lt 40 to
    comparable community J Infect Dis 197012216
  • Texas community ? flu vaccination rate 15 ?
    30, significantly lowered risk respiratory
    illness in children and adults gt35 yo Vaccine
    2005231540
  • Stochastic flu simulation model (Longini,
    Atlanta, Oct 2005) Vaccination 20 children 5-18
    yo ? all age mortality 40 Vaccination
    50 children ? all age mortality 75
  • (www.medicine.emory.edu/id/ecirve/faculty_spea
    ker_slides/longiniflu)

11
INFLUENZA PEDIATRIC POPULATION
  • Children play a significant role in the
    introduction and spread of influenza virus into
    households and in the community. Cases among
    school-age children usually peak in the early
    stage of an epidemic and are followed by cases in
    infants and adults. The presence of school age
    children in the household is the most important
    determinant related to the occurrence of
    influenza infection. There is also evidence that
    seroconversion to influenza virus in children
    continues to occur between epidemic, suggesting
    persistence of viral activity throughout the
    year. Munoz. Paediatr Respir Rev
    2003499-104

12
CATEGORY 4/5 PANDEMIC
  • Very Severe 1918-1920 (H1N1) like Clinical
    attack rate 20-40, Case fatality ratio gt 2,
    Excess death rate gt 500 cases/100,000
  • Community Mitigation Procedures All schools
    and day cares close for 12 weeks Children/teen
    congregation limited Social distancing
    adult/teen/children Home isolation ill no
    hospital surge capacity Home quarantine
    (voluntary) household contact
  • Goal Cut the death rate Minimize attack rate
    ?Impact economy/security/mental health Flatten
    and broaden epidemiologic curve

13
NEURAMINIDASE INHIBITORS Oseltamivir Tamiflu TM
(Roche)
  • Age limit gt1 years
  • Treatment use Initiate lt 2 days symptoms Dose -
    75mg oral 2X/day Efficacy- ? severity symptoms
    1 day ? elderly hospitalization
    (initiate 24 hr)
  • Children ? symptoms 1.5 days ? asthma
  • Prophylaxis 75mg qd - initiated in 2 days of
    index case symptoms high prophylactic
    efficacy in 4 household studies - oseltamivir
    (81) zanamivir (75). Oseltamivir ?
    infectiousness 80 ? pathogenicity (cause
    disease) 79/56 Am J Epidemiology
    2006 Nov 6 (doi10.1093/aje/kwj362)

14
NEURAMINIDASE INHIBITORS Oseltamivir Tamiflu TM
(Roche)
  • Avian flu strains (H5N1,H7N3, H7N7,
    H9N2) Suspect cases, early treatment (prior
    lab tests) dose?
  • Prophylaxis (AHFS Drug Information
    2006) HCW respiratory secretions (droplet)
    Household contacts confirmed cases
    Poultry/contaminated surface direct
    contact Post panflu immunization (2
    wks) Long term (4 weeks) during waves
  • Cost 46.50 Navy Pharmacy (10 tabs BID 5 days)/
    shelf life 5 years. Federal stockpile cost listed
    15 Euros 18.81
  • US National stockpile FY06 purchases to 20M
    courses Oregon (Pop 3.5M) allotment FY06 - 241K
    (374K with optional 25 state purchase) FY07
    total Fed allotment ?531K (http//pandemicflu.g
    ov/plan/states/antivirals.html)

15
NEURAMINIDASE INHIBITORS Zanamivir RelenzaTM
(GlaxoSmithKline)
  • Age limit gt7 years
  • Treatment use Initiate lt 2 days symptoms Dose
    - 5mg inhalation 2X/day for 5 days
  • Special use Oseltamivir resistance
  • Pregnancy preferred
  • Concerns Bronchospasm in COPD/Asthma Young
    children use of inhaler
  • Side effects 1-3 (very low rate) diarrhea,
    nausea, vomiting, bronchitis, sinusitis, no CNS
    issues like amantidine/rimantidine

16
NEURAMINIDASE INHIBITORS ACIP/NVAC
PRIORITIZATION
  • Treatment hospitalized patients health care
    workers (HCW) with direct patient contact and
    EMS pandemic health responders public safety
    and key government decision makers high risk
    individuals (immunocompromised, elderly,lt1yo)
  • Post exposure prophylaxis certain institutions
    (nursing homes), EMS workers HCWs-ERS, ICU,
    Dialysis units,
  • Outpatient treatment
  • Prophylaxis high risk patients, other HCWs
    patient contact
  • ACIPAdvisory Committee on Immunization Practice
    NVAPNational Vaccine Advisory Committee
    Ref AHFS Drug
    Information 2006

17
INTERVENTIONS
  • Targeted Layer Containment (TLC) Response
    geared to severity
  • Non-Pharmaceutical Interventions (NPI) Public
    education - cough etiquette, wash hands,
    Masks/Respirators (N95)-large droplet/airborne S
    ocial distancing-avoid close contact outside
    home Congregations discouraged Isolat
    ion of ill/ Quarantine of exposed
  • NPI effectiveness evidence thin and
    controversial IOM- Panflu modeling/containment
    report 25-26 Oct 2006, Washington DC DTRA-
    Workshop on panflu1918 lesson learned 6-7 April
    2006 (www.dtra.mil/documents/be/pandemicworkshop
    report.pdf)
  • Protective sequestration early community
    isolation Navy Base Goat Island Yerba Buena,
    CA San Francisco Bay 1918 Markel et al Emerg
    Infect Dis 2006121961

18
CONTINUITY OF OPERATIONS
  • Pandemic vaccine prioritization (18 months for
    appropriate supplies)
  • Neuraminidase (Oseltamivir) prophylaxis/treat
  • Family demands ill members or children at home
  • Threat actual/perceived occupational
    exposure 6500 HCW survey NYC most willing
    to report snowstorm (80) least willing SARS
    (48) most able to report mass casualty
    (81) least able smallpox (67) Qureshi
    et al. J Urban Health 20582378
Write a Comment
User Comments (0)
About PowerShow.com